What Therapeutic Strategies Target Control Proteins?
Targeting dysregulated control proteins has become a promising strategy in cancer therapy. For example, CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib have shown efficacy in treating cancers with overactive CDK4/6. Restoring the function of p53 through small molecules or gene therapy is another area of active research. Additionally, targeting the pathways that regulate Rb phosphorylation is being explored to prevent its inactivation in cancer cells.
